Prostate Cancer and the Mevalonate Pathway

Area of Science:

• Oncology
• Cancer Metabolism
• Prostate Cancer Research

Background:

• Androgen receptor (AR) pathway is a primary target for prostate cancer (PCa) antineoplastic therapies.
• Tumor resistance to monomolecular treatments necessitates diversification of therapeutic strategies.
• Emerging evidence highlights the role of metabolic pathways in cancer progression and treatment resistance.

Purpose of the Study:

• To review the role of lipid metabolism dysregulation in prostate cancer survival.
• To explore how targeting lipid metabolism can overcome treatment resistance in PCa.
• To emphasize the integration of metabolic insights into future PCa management.

Main Methods:

• Literature review of studies on prostate cancer, androgen receptor pathway, and lipid metabolism.
• Analysis of mechanisms by which tumors utilize lipid metabolism for survival.
• Synthesis of current understanding of resistance mechanisms in PCa treatment.

Main Results:

• Dysregulation of lipid metabolic pathways is a key survival strategy for prostate tumors.
• Tumors adapt their metabolism to evade eradication efforts, particularly under AR-targeted therapy.
• Lipid metabolism alterations are intrinsically linked to the development of treatment resistance.

Conclusions:

• Targeting lipid metabolism presents a promising avenue for overcoming resistance in prostate cancer.
• Integrating metabolic pathway modulation into oncological management could enhance PCa treatment efficacy.
• Diversifying therapeutic strategies beyond the AR pathway to include metabolic interventions is crucial for combating advanced PCa.